Drilldown: Medicines
Medicines > classes:
[[:Category:Antimuscarinics|Antimuscarinic]] 
& routes :
Oral or
soft-mist inhaler)
& routes :
Oral or
soft-mist inhaler) Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
uses:
starting dose:
preparations:
10, 20 mg tablets/capsules; 10 mg/5 mL syrup; 10 mg/mL IM injection (1) ·
18 mcg HandiHaler capsules; 2.5 mcg/actuation Respimat solution inhaler (1.25 mcg/actuation for asthma indication) (1) ·
5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel (1)
fda max:
routes: (Click arrow to add another value)
onset:
duration:
halflife:
bioavailability:
Inhaled lung deposition ~20%; systemic absorption from lung ~33%; oral component negligible'"`UNIQ--ref-000009C1-QINU`"' (1) ·
~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' (1) ·
~67% (oral)'"`UNIQ--ref-00000B26-QINU`"' (1)
pregnancy:
Generally avoided; not first-line.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; LABA/LAMA strategies in pregnancy generally favor agents with the most reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 3 results in range #1 to #3.